Top

Published in:

01-06-2011 | Review

Predictive biomarkers for the activity of mammalian target of rapamycin (mTOR) inhibitors

Authors: Catherine Delbaldo, Sébastien Albert, Chantal Dreyer, Marie-Paule Sablin, Maria Serova, Eric Raymond, Sandrine Faivre

Published in: Targeted Oncology | Issue 2/2011

Abstract

In the quest for personalized medicine, only a few biological parameters are routinely used to select patients prior to the initiation of anticancer targeted therapies, including mTOR inhibitors. Identifying biological factors that may predict efficacy or resistance to mTOR inhibitors represents an important challenge since rapalogs may exert antitumor effects through multiple mechanisms of action. Despite the fact that no such a factor is currently available, several molecular patterns are emerging, correlating with sensitivity and/or resistance to rapalogs. While activation of the phosphatidylinositol 3 kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, overexpression of cyclin D1, and functional apoptosis seem to sensitize tumor cells to rapalogs, Bcl2 overexpression or KRAS mutations are reported to be associated with resistance to mTOR inhibitors in several preclinical models. Translational research aimed at validating those parameters in clinical trials is ongoing.

Albert S, Serova M, Dreyer C et al (2010) New inhibitors of the mammalian target of rapamycin signaling pathway for cancer. Expert Opin Investig Drugs 19:919–930PubMedCrossRef

Faivre S, Kroemer G, Raymond E (2006) Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 5:671–688PubMedCrossRef

Le Tourneau C, Faivre S, Serova M et al (2008) mTORC1 inhibitors: is temsirolimus in renal cancer telling us how they really work? Br J Cancer 99:1197–1203PubMedCrossRef

Faivre S, Raymond E (2008) Mechanism of action of rapalogues: the antiangiogenic hypothesis. Expert Opin Investig Drugs 17:1619–1621PubMedCrossRef

O’Donnell A, Faivre S, Burris HA 3rd et al (2008) Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol 26:1588–1595PubMedCrossRef

Neshat MS, Mellinghoff IK, Tran C et al (2001) Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci USA 98:10314–10319PubMedCrossRef

Noh WC, Mondesire WH, Peng J et al (2004) Determinants of rapamycin sensitivity in breast cancer cells. Clin Cancer Res 10:1013–1023PubMedCrossRef

Grunwald V, DeGraffenried L, Russel D et al (2002) Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells. Cancer Res 62:6141–6145PubMed

Hara S, Oya M, Mizuno R et al (2005) AKT activation in renal cell carcinoma: contribution of a decreased PTEN expression and the induction of apoptosis by an AKT inhibitor. Ann Oncol 16:928–933PubMedCrossRef

10.

Hay N (2005) The Akt-mTOR tango and its relevance to cancer. Cancer Cell 8:179–183PubMedCrossRef

11.

Wang X, Yue P, Kim YA et al (2008) Enhancing mammalian target of rapamycin (mTOR)—targeted cancer therapy by preventing mTOR/Raptor inhibition-initiated, mTOR/Rictor-Independent Akt Activation. Cancer Res 68:7409–7418PubMedCrossRef

12.

Dibble CC, Manning BD (2009) A molecular link between AKT regulation and chemotherapeutic response. Cancer Cell 16:178–180PubMedCrossRef

13.

Fuchs BC, Fujii T, Dorfman JD et al (2008) Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to Epidermal Growth Factor receptor inhibition in human hepatoma cells. Cancer Res 68:2391–2399PubMedCrossRef

14.

Zhao L, Vogt PK (2008) Class I PI3K in oncogenic cellular transformation. Oncogene 27:5486–5496PubMedCrossRef

15.

Di Nicolantonio F et al (2010) Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. J Clin Invest 20:2858–2866CrossRef

16.

Witzig TE, Geyer SM, Ghobrial I et al (2005) Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 23:5347–5356PubMedCrossRef

17.

Hess G, Herbrecht R, Romaguera J et al (2009) Phase III study to evaluate temsirolimus compared with investigator’s choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 27:3822–3829PubMedCrossRef

18.

Figlin RA, de Souza P, McDermott D et al (2009) Analysis of PTEN and HIF-1a and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon-a. Cancer 115:3651–3660PubMedCrossRef

19.

Bae-Jump VL, Zhou C, Boggess JF et al (2010) Rapamycin inhibits cell proliferation in type I and type II endometrial carcinomas: a search for biomarkers of sensitivity to treatment. Gynecol Oncol 119:579–585PubMedCrossRef

20.

Yu K, Toral-Barza L, Discafani C et al (2001) mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr Relat Cancer 8:249–258PubMedCrossRef

21.

Yang L, Clarke MJ, Carlson BL et al (2008) PTEN loss does not predict for response to RAD001 (Everolimus) in a glioblastoma orthotopic xenograft test panel. Clin Cancer Res 14:3993–4001PubMedCrossRef

22.

Raymond E, Alexandre J, Faivre S et al (2004) Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 22:2336–2347PubMedCrossRef

23.

Hudes G, Carducci M, Tomczak P et al (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356:2271–2281PubMedCrossRef

24.

Raymond E, Dahan L, Raoul JL et al (2011) Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364:501–513PubMedCrossRef

25.

Yao JC, Shah MH, Ito T et al (2011) Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364:514–523PubMedCrossRef

26.

Aguirre D et al (2004) Bcl-2 and CCND1/CDK4 expression levels predict the cellular effects of mTOR inhibitors in human ovarian carcinoma. Apoptosis 9:797–805PubMedCrossRef

27.

Majumder PK, Febbo PG, Bikoff R et al (2004) mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 10:594–601PubMedCrossRef

28.

Aissat N, Le Tourneau C, Ghoul A et al (2008) Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines. Cancer Chemother Pharmacol 62:305–313PubMedCrossRef

29.

Wangpaichitr M, Wu C, You M et al (2008) Inhibition of mTOR restores cisplatin sensitivity through down-regulation of growth and anti-apoptotic proteins. Eur J Pharmacol 591:124–127PubMedCrossRef

Title: Predictive biomarkers for the activity of mammalian target of rapamycin (mTOR) inhibitors
Authors: Catherine Delbaldo
Sébastien Albert
Chantal Dreyer
Marie-Paule Sablin
Maria Serova
Eric Raymond
Sandrine Faivre
Publication date: 01-06-2011
Publisher: Springer-Verlag
Published in: Targeted Oncology / Issue 2/2011
Print ISSN: 1776-2596
Electronic ISSN: 1776-260X
DOI: https://doi.org/10.1007/s11523-011-0177-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2011

Targeting phosphatidylinositol 3 kinase (PI3K)-Akt beyond rapalogs

Regulation of mammalian target of rapamycin complex 1 (mTORC1) by hypoxia: causes and consequences

Clinical activity of mammalian target of rapamycin inhibitors in solid tumors

Mammalian target of rapamycin expression in poorly differentiated endocrine carcinoma: clinical and therapeutic future challenges

Common toxicities of mammalian target of rapamycin inhibitors

Are we ready to move away from nature? The rapamycin story

Keynote webinar | Spotlight on antibody–drug conjugates in cancer